Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

Insiders have been trading these 5 stocks: (($TRV)), (($TDG)), (($CYTK)), (($GLBE)) and (($CBIO)). Here is a breakdown of their recent trades and t...

Travelers, TransDigm, Cytokinetics, Global-e, Crescent Shock Moves

The latest announcement is out from BB Biotech ( ($CH:BION) ). BB Biotech AG, a specialist biotech investment company listed in Switzerland and Ger...

BB Biotech posts strong interim profit and shifts to yield-based dividend policy

An update from BB Biotech ( ($CH:BION) ) is now available. BB Biotech reported a strong second quarter of 2026, with its net asset value delivering...

BB Biotech posts strong Q2, boosts AI-driven investing and revises dividend policy

WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Biosynex SA ( ($FR:ALBIO) ) just unveiled an announcement. Biosynex reported first-half 2026 revenue of €44.1M, a 13% year-on-year decline, as its ...

Biosynex H1 Revenue Falls as Restructuring and Debt Safeguard Progress

Ibio ( ($IBIO) ) has shared an update. iBio, Inc. has scheduled its 2026 Annual Meeting of Stockholders for October 14, 2026, with a record date of...

iBio Updates Governance Deadlines for 2026 Annual Meeting

Berenberg Bank analyst Harry Gillis maintained a Buy rating on Swedish Orphan Biovitrum AB yesterday and set a price target of SEK575.00. The compa...

Berenberg Bank Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RxSight (RXST), Kazia Therapeutics (KZIA) and Cres...

Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)

An update from Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) is now available. Sobi reported strong second-quarter 2026 results, with total revenue ri...

Sobi lifts 2026 outlook as Q2 revenue surges and gout pipeline advances

Swedish Orphan Biovitrum AB ( ($SE:SOBI) ) has shared an update. Sobi’s board has decided to repurchase all issued class C shares to secure the com...

Sobi Moves to Repurchase Class C Shares to Support Employee Incentive Programme

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO), Healthequity (HQY) and Alny...

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Healthequity (HQY) and Alnylam Pharma (ALNY)

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma today and set a price target of $111.00. According to TipRanks, Amin i...

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

RBC Capital analyst Luca Issi maintained a Buy rating on BridgeBio Pharma on July 7 and set a price target of $100.00. The company’s shares closed ...

RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

A federal judge in Massachusetts has dismissed a securities lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO), ruling that the clinical-stage bi...

Court Dismisses Securities Lawsuit Against Zenas BioPharma Over IPO Disclosures 

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and Bridge...

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

BridgeBio Pharma ( ($BBIO) ) has provided an update. On July 1, 2026, BridgeBio Pharma entered into an investment agreement with funds managed by S...

BridgeBio Raises $934 Million via Preferred Equity Financing

In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on Biome Australia Ltd, with a price target of A$0.75. According...

Bell Potter Keeps Their Buy Rating on Biome Australia Ltd (BIO)

An update from Jade Biosciences ( ($JBIO) ) is now available. On June 29, 2026, Jade Biosciences entered into a worldwide, exclusive license agreem...

Jade Biosciences Secures Exclusive Antibody License Agreement

The latest update is out from Ibio ( ($IBIO) ). On July 1, 2026, iBio reported new preclinical data from an obese non-human primate study of IBIO-6...

iBio Highlights Promising New Preclinical Obesity Antibody Data

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), BridgeBio Pharma (BBIO) and Jazz Pharm...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$316.41	+0.62%	348.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$316.41	+0.6%	348.90K
3
4
5
6

BIO

BIO

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel